The diagnosis and management of hepatitis C: The role of the physician assistant

Internet Journal of Academic Physician Assistants

Volumn 5, Issue 2, 2007, Pages

  Neighbors, Julie ^a  

^a Austin Gastroenterology   (United States)

Author keywords

Diagnosis; Hepatitis C virus; Peginterferon; Ribavirin

Indexed keywords

EID: 33847639651     PISSN: 10924078     EISSN: 10924078     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-S34.
2. National Institutes of Health. Management of hepatitis C: 2002. NIH Consensus Statement 2002;19:1-46.
3. Alter M, Kruszon-Moran D, Nainan O, McQuillan G, Gao F, Moyer L, Kaslow R, Margolis H. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
4. Centers for Disease Control. Disease burden from hepatitis A, B, and C in the United States. Available at: [www.cdc.gov/ncidod/diseases/hepa ... ] . Accessed February 10, 2006.
5. Ortiz JA, Lane CT. Hepatitis C: expected to kill more Americans than AIDS by 2020, hepatitis C is emerging from the shadows. Available at: [www.hippocrates.com/archive/Nove ... ] . Accessed October 26, 2004.
6. Poynard T, Bedossa P, Opolon P. , for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
7. Strader DB, Wright T, Thomas DL, Seeff LB. ASSLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
8. Centers for Disease Control. National hepatitis C prevention strategy: hepatitis C infection in the United States. Available at: [www.cdc.gov/ncidod/ diseases/hepa ... ] . Accessed October 27, 2004.
9. Deuffic-Burban S, Wong J, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in United States. Poster presented at: 54th annual meeting of the American Association for the Study of Liver Diseases. Available at: [www.hivandhepatitis.com/2003icr/ ... ] . Accessed September 24, 2004.
10. Pawlotsky J-M. Treating hepatitis C in "difficult-to-treat" patients [perspective]. N Engl J Med 2004;351:422-423.
11. Perry CM, Jarvis B. Peginterferon-a-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs 2001;61:2263-2288.
12. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002;24:1363-1383.
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M-H, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. , and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FJ, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
15. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HJ, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, for the PEGASYS International Study Group. Peginterferon-μ 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
16. Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care 2004;10:250-256.
17. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
18. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. The PEG-FIBROSIS Project Group. Gastroenterology 2002;122:1303-1313.
19. Gujral H, Viscomi C, Collantes R. The role of physician extenders in managing patients with chronic hepatitis C. Cleveland Clin J Med 2004;71(suppl 3):S33-S37.
20. Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. Hepatology 2004;39:1204-1212.
21. Kenny-Walsh E. , for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.
22. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
23. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-143.
24. Stephenne X, Sokal EM. Hepatitis C in children and adolescents: mode of acquisition, natural history and treatment. Acta Gastroenterol Belg 2002;65:95-98.
25. Haley RW, Fischer RP. The tattooing paradox: are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? Arch Intern Med 2003;163:1095-1098.
26. Hayes MO, Harkness GA. Body piercing as a risk factor for viral hepatitis: an integrative research review. Am J Infect Control 2001;29:271-274.
27. Leung NW. Management of viral hepatitis C. J Gastroenterol Hepatol 2002;17(suppl):S146-S154.
28. Ernst E, Sherman KJ. Is acupuncture a risk factor for hepatitis? Systematic review of epidemiological studies. J Gastroenterol Hepatol 2003;18:1231-1236.
29. El-Serag HB, Anand B, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 2003;98:167-174.
30. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998;47(RR-19):1-39.
31. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(3 suppl 1):15S-20S.
32. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
33. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003;42:631-657.
34. Szabó E, Lotz G, Páska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection [review]. Pathol Oncol Res 2003;9:215-221.
35. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia MT, Zignego AL. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 2003;21(suppl 32):S78-S84.
36. Schering Corporation. PEG-Intron® Redipenä Single-Dose Delivery System (peginterferon alfa-2b) package insert. Kenilworth, NJ; 2003.
37. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006;101:76-82.
38. Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H, Stuver SO. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 2006.
39. Reddy SI, Ukomadu C. Hepatitis C: update on management of chronic infection. J Clin Outcomes Manage 2004;11:523-533.
40. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm Rep 2003;52(RR-03):1-16.
41. Pawlotsky J-M. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics. Semin Liver Dis 2003;23(suppl 1):3-11.
42. Dal Molin G, Tiribelli C, Campello C. A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection. [review]. Ann Hepatol 2003;2:76-83.
43. Ward RP, Kugelmas M, Libsch KD. Management of hepatitis C: evaluating suitability for drug therapy. Am Fam Phys 2004;69:E1429-E1438.
44. American Gastroenterological Association. AGA news releases: stigma of hepatitis C and lack of awareness stops Americans from getting tested and treated. Available at: [www.gastro.org/media/newsRelease ... ] . Accessed October 26, 2004.
45. Jessop AB, Cohen C, Burke MM, Conti M, Black M. Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nurs 2004;27:163-169.
46. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002;36(5 suppl 1):S99-S105.
47. Herrine SK. Approach to the patient with chronic hepatitis C virus infection [review]. Ann Intern Med 2002;136:747-757.
48. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(suppl 1):S237-S244.